
Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-4... Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.3 | 0.3 | 0.3 | 0 | 0 | CS |
4 | 0 | 0 | 0.3 | 0.3 | 0.3 | 0 | 0 | CS |
12 | -0.1421 | -32.1420493101 | 0.4421 | 0.45999 | 0.3 | 18237 | 0.32385971 | CS |
26 | -0.6 | -66.6666666667 | 0.9 | 0.9384 | 0.3 | 71509 | 0.50582924 | CS |
52 | -1.52 | -83.5164835165 | 1.82 | 3.49 | 0.3 | 650304 | 1.77881684 | CS |
156 | -339.94 | -99.9118269457 | 340.24 | 860 | 0.3 | 2214373 | 56.06286938 | CS |
260 | -239.7 | -99.875 | 240 | 1548 | 0.3 | 1765397 | 181.72866324 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約